Clinical trial
A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult…
NCT00495287 · Northern Italy Leukemia Group, Other · Completed
Key facts
| NCT number | NCT00495287 |
|---|---|
| Title | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) |
| Official title | Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program |
| Lead sponsor | Northern Italy Leukemia Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | cytosine arabinoside |
| Enrollment | 573 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2015 |
| Completion | Dec 1, 2015 |
| First posted | Jul 3, 2007 |
| Last update posted | Mar 31, 2016 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: